PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP InhibitionYasir H. Ibrahim, José Baselga, Celina García-García et al.|Cancer Discovery|2012Cited by 622
Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trialsTimothy A. Yap, Marina Konopleva, Prithviraj Bose et al.|Nature Medicine|2023Cited by 372
BRAF Inhibition in <i>BRAF</i> <sup>V600</sup> -Mutant Gliomas: Results From the VE-BASKET StudyThomas Kaley, David M. Hyman, Mehdi Touat et al.|Journal of Clinical Oncology|2018Cited by 330
Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancerAna C. Garrido-Castro, Jordi Rodón|Breast Cancer Research|2020Cited by 145
Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendationsZeid Kuzbari, Chaitanya Bandlamudi, Chey Loveday et al.|Annals of Oncology|2022Cited by 133